22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › KURA ONCOLOGY INC. › 2024-2025

KURA ONCOLOGY INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KURA ONCOLOGY INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 184Asset managers, any item
  • 1,236Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 6 items on KURA ONCOLOGY INC.’s Form 8-K, filed June 6, 2025: 3 approved · 3 passed (calculated).

Dissent

Notable dissent: 3 directors (17.7%, 14.5%, 14.5% against); 1 other board item (18.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KURA ONCOLOGY INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KURA ONCOLOGY INC.

These tallies are KURA ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KURA ONCOLOGY INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Helen Collins, M.D. 55,377,590---- 9,392,6555,864,331 85%Passed (calculated)—
Elect Director: Thomas Malley 53,300,572---- 11,469,6735,864,331 82%Passed (calculated)—
Elect Director: Carol Schafer 55,407,228---- 9,363,0175,864,331 86%Passed (calculated)—
2. Ratification of the Appointment of Independent Registered Public Accounting Firm 70,490,63072,93671,010 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 63,155,7961,522,75491,695 --5,864,331 98%Approved—
4. Approval of our Amended 2014 Plan 53,050,06311,634,75585,427 --5,864,331 82%Approved—

Source: KURA ONCOLOGY INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.

How asset managers voted at the KURA ONCOLOGY INC. 2024-2025 meeting

184 asset managers disclosed a vote on at least one KURA ONCOLOGY INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Carol Schafer

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD
FOR: 55,407,228WITHHELD: 9,363,017
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class II directors for three-year terms: Carol Schafer

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Carol Schafer”): 55,407,228 for, 9,363,017 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 13,062,881 for, 3,020,824 withheld.

FORWITHHOLD
FOR: 13,062,881WITHHOLD: 3,020,824
Largest asset managers voting on “Election of three Class II directors for three-year terms: Carol Schafer” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,0270 0800For
State Street1,618,6320 01,866For
FRANKLIN STRATEGIC SERIES00 0761,091Withhold
Dimensional00 0684,977Withhold
Charles Schwab00 0622,972Withhold
TIAA233,1670 00For
Equitable117,3670 083,100Mixed
Exchange Place Advisors Trust00 0193,488Withhold
Prudential/PGIM134,3470 011,055Mixed
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial77,4460 047,045Mixed
Putnam95,0130 00For
PACE SELECT ADVISORS TRUST00 072,226Withhold
American Century00 068,322Withhold
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica00 047,637Withhold
Northern Trust47,2740 00For
Direxion Shares ETF Trust00 044,590Withhold
ProShares00 044,546Withhold
Global X00 043,592Withhold
Voya39,6850 00For
PFM Multi-Manager Series Trust00 039,024Withhold

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Helen Collins, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 55,377,590WITHHELD: 9,392,655
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class II directors for three-year terms: Helen Collins, M.D.

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Helen Collins, M.D.”): 55,377,590 for, 9,392,655 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 13,062,953 for, 3,020,752 withheld.

FORWITHHOLD
FOR: 13,062,953WITHHOLD: 3,020,752
Largest asset managers voting on “Election of three Class II directors for three-year terms: Helen Collins, M.D.” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,0270 0800For
State Street1,618,6320 01,866For
FRANKLIN STRATEGIC SERIES00 0761,091Withhold
Dimensional00 0684,977Withhold
Charles Schwab00 0622,972Withhold
TIAA233,1670 00For
Equitable117,3670 083,100Mixed
Exchange Place Advisors Trust00 0193,488Withhold
Prudential/PGIM134,3470 011,055Mixed
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial77,4460 047,045Mixed
Putnam95,0130 00For
PACE SELECT ADVISORS TRUST00 072,226Withhold
American Century00 068,322Withhold
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica00 047,637Withhold
Northern Trust47,2740 00For
Direxion Shares ETF Trust00 044,590Withhold
ProShares00 044,546Withhold
Global X00 043,592Withhold
Voya39,6850 00For
PFM Multi-Manager Series Trust00 039,024Withhold

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Thomas Malley

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 53,300,572WITHHELD: 11,469,673
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class II directors for three-year terms: Thomas Malley

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Thomas Malley”): 53,300,572 for, 11,469,673 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 12,963,093 for, 3,120,612 withheld.

FORWITHHOLD
FOR: 12,963,093WITHHOLD: 3,120,612
Largest asset managers voting on “Election of three Class II directors for three-year terms: Thomas Malley” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,0270 0800For
State Street3,9240 01,616,574Withhold
FRANKLIN STRATEGIC SERIES761,0910 00For
Dimensional00 0684,977Withhold
Charles Schwab622,9720 00For
TIAA233,1670 00For
Equitable117,3670 083,100Mixed
Exchange Place Advisors Trust193,4880 00For
Prudential/PGIM134,3470 011,055Mixed
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial23,6470 0100,844Mixed
Putnam95,0130 00For
PACE SELECT ADVISORS TRUST00 072,226Withhold
American Century00 068,322Withhold
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica00 047,637Withhold
Northern Trust00 047,274Withhold
Direxion Shares ETF Trust00 044,590Withhold
ProShares00 044,546Withhold
Global X43,5920 00For
Voya00 039,685Withhold
PFM Multi-Manager Series Trust00 039,024Withhold

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Approval of our Amended 2014 Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

82% Approved · of votes cast

FOR 82%AGAINST
FOR: 53,050,063AGAINST: 11,634,755
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.

KURA ONCOLOGY INC.’s own tally for this item (“4. Approval of our Amended 2014 Plan”): 53,050,063 for, 11,634,755 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) approved our Amended 2014 Plan”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,027800 00For
State Street1,618,6321,866 00For
FRANKLIN STRATEGIC SERIES761,0910 00For
Dimensional0684,977 00Against
Charles Schwab622,9720 00For
TIAA0233,167 00Against
Equitable117,36783,100 00Mixed
Exchange Place Advisors Trust193,4880 00For
Prudential/PGIM0145,402 00Against
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial77,44647,045 00Mixed
Putnam095,013 00Against
PACE SELECT ADVISORS TRUST072,226 00Against
American Century068,322 00Against
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica047,637 00Against
Northern Trust047,274 00Against
Direxion Shares ETF Trust044,590 00Against
ProShares044,546 00Against
Global X43,5920 00For
Voya039,685 00Against
PFM Multi-Manager Series Trust039,024 00Against

Fund voting reports, all 57 managers: 14,157,181 for, 1,918,205 against, 8,319 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ALGERT GLOBAL LLC216,4580 00For

Institutional-manager reports, all 1 managers: 216,458 for.

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 63,155,796AGAINST: 1,522,754

Prior year: 91.9% for (June 5, 2024 meeting) ▲ 5.8 pts

Details: description as filed, official tally, votes by 184 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement.

KURA ONCOLOGY INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 63,155,796 for, 1,522,754 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,8270 00For
State Street1,620,083415 00For
FRANKLIN STRATEGIC SERIES761,0910 00For
Dimensional684,9770 00For
Charles Schwab622,9720 00For
TIAA233,1670 00For
Equitable200,4670 00For
Exchange Place Advisors Trust193,4880 00For
Prudential/PGIM145,4020 00For
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial124,4910 00For
Putnam95,0130 00For
PACE SELECT ADVISORS TRUST72,2260 00For
American Century068,322 00Against
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica47,6370 00For
Northern Trust47,2740 00For
Direxion Shares ETF Trust44,5900 00For
ProShares44,5460 00For
Global X43,5920 00For
Voya39,6850 00For
PFM Multi-Manager Series Trust39,0240 00For

Fund voting reports, all 57 managers: 15,994,501 for, 80,885 against, 8,319 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 149 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL7,754,1290 00For
SUVRETTA CAPITAL MANAGEMENT, LLC7,452,3880 00For
ARMISTICE CAPITAL, LLC6,027,4760 00For
RA CAPITAL MANAGEMENT, L.P.3,957,6370 00For
BlackRock3,551,30838,150 00For
State Street3,095,043625 00For
GEODE CAPITAL MANAGEMENT, LLC1,808,3020 00For
FRANKLIN ADVISERS INC1,362,8710 00For
JACOBS LEVY EQUITY MANAGEMENT, INC1,076,4410 00For
TCG Crossover Management, LLC735,1840 00For
Charles Schwab622,9720 00For
Prosight Management, LP599,1240 00For
Northern Trust541,0410 00For
Sofinnova Investments, Inc.498,8460 00For
Foresite Capital Management IV, LLC498,0150 00For
DAFNA Capital Management LLC463,3680 00For
SILVERARC CAPITAL MANAGEMENT, LLC463,0650 00For
1492 Capital Management LLC399,8030 00For
AQR334,6500 00For
JPMorgan325,7020 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC258,0160 00For
Russell Investments254,9370 00For
Voss Capital, LP249,8710 00For
MELLON INVESTMENTS Corp244,5090 00For
Nuveen236,9470 00For

Institutional-manager reports, all 149 managers: 45,455,797 for, 399,450 against, 8,992 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 70,490,630AGAINST: 72,936

Prior year: 99.9% for (June 5, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

KURA ONCOLOGY INC.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 70,490,630 for, 72,936 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 16,075,322 for, 64 against, 8,319 abstained.

FOR
FOR: 16,075,322AGAINST: 64ABSTAIN: 8,319
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at KURA ONCOLOGY INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,858,9020 00For
BlackRock3,761,8310 00For
Fidelity1,638,8270 00For
State Street1,620,43464 00For
FRANKLIN STRATEGIC SERIES761,0910 00For
Dimensional684,9770 00For
Charles Schwab622,9720 00For
TIAA233,1670 00For
Equitable200,4670 00For
Exchange Place Advisors Trust193,4880 00For
Prudential/PGIM145,4020 00For
JPMorgan133,0130 00For
QUANTITATIVE MASTER SERIES LLC125,3920 00For
Lincoln Financial124,4910 00For
Putnam95,0130 00For
PACE SELECT ADVISORS TRUST72,2260 00For
American Century68,3220 00For
MASTER INVESTMENT PORTFOLIO62,4290 00For
AIG/SunAmerica47,6370 00For
Northern Trust47,2740 00For
Direxion Shares ETF Trust44,5900 00For
ProShares44,5460 00For
Global X43,5920 00For
Voya39,6850 00For
PFM Multi-Manager Series Trust39,0240 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Largest KURA ONCOLOGY INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 80,778,000 shares outstanding at the time of that meeting.

Fund voting reports: top KURA ONCOLOGY INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers, as…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 6.02%
2BlackRock 4.66%
3Fidelity 2.03%
4State Street 2.01%
5FRANKLIN STRATEGIC SERIES 0.94%
6Dimensional 0.85%
7Charles Schwab 0.77%
8TIAA 0.29%
9Equitable 0.25%
10Exchange Place Advisors Trust 0.24%
Institutional-manager reports: top KURA ONCOLOGY INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers, as…”, 2024-2025
#Asset manager % of shares outstanding
1BVF INC/IL 9.60%
2SUVRETTA CAPITAL MANAGEMENT, LLC 9.23%
3ARMISTICE CAPITAL, LLC 7.46%
4RA CAPITAL MANAGEMENT, L.P. 4.90%
5BlackRock 4.44%
6State Street 3.83%
7GEODE CAPITAL MANAGEMENT, LLC 2.24%
8FRANKLIN ADVISERS INC 1.69%
9JACOBS LEVY EQUITY MANAGEMENT, INC 1.33%
10TCG Crossover Management, LLC 0.91%

Reported KURA ONCOLOGY INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KURA ONCOLOGY INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BVF PARTNERS L P/IL8,677,018 10.74%Schedule 13G, filed November 14, 2025
BlackRock8,177,646 10.12%Form 13F, quarter ended March 31, 2025
SUVRETTA CAPITAL MANAGEMENT, LLC7,561,000 9.36%Schedule 13G, filed May 2, 2025
Vanguard Group4,948,235 6.13%Form 13F, quarter ended March 31, 2025
RA Capital Management, L.P.4,368,998 5.41%Proxy statement (DEF 14A), proxy filed April 11, 2025
EcoR1 Capital, LLC4,200,000 5.20%Schedule 13G, filed August 14, 2025
Armistice Capital, LLC3,736,000 4.63%Schedule 13G, filed May 15, 2026
State Street3,282,080 4.06%Form 13F, quarter ended March 31, 2025
Troy E. Wilson, Ph.D., J.D.2,807,964 3.48%Proxy statement (DEF 14A), proxy filed April 11, 2025
Morgan Stanley1,923,158 2.38%Form 13F, quarter ended March 31, 2025

Percentages above are of 80,778,000 shares outstanding, as reported by KURA ONCOLOGY INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KURA ONCOLOGY INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 184 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,236 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers, as… — KURA ONCOLOGY INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KURA ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KURA ONCOLOGY INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KURA ONCOLOGY INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “KURA ONCOLOGY (KURA) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/kura-oncology-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.